Patent application number | Description | Published |
20090155853 | NON-VIRAL GENE DELIVERY COMPLEX - The invention relates to fusion proteins useful in delivering a targeted nucleic acid to a target cell, comprising a gene delivery fusion protein (GDFP), said GDFP comprising a nucleic acid binding domain (NBD) that binds to the targeted nucleic acid, fused to a gene delivery domain (GDD) that mediates delivery of the targeted nucleic acid to the target cell, wherein said GDD comprises one or more components that facilitate delivery of a targeted nucleic acid to a target cell, and wherein one of said components is a transport/localization component and wherein said transport/localization component is an adenovirus protein V or derivative thereof that retains protein V activity, and related methods of making and using thereof. | 06-18-2009 |
20120003266 | VIRUS LIKE PARTICLE COMPOSITIONS AND METHODS OF USE - The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases. | 01-05-2012 |
20130251744 | VIRUS LIKE PARTICLE COMPOSITION - The present invention provides a particle comprising a polypeptide and at least one antigen, and a composition comprising thereof. | 09-26-2013 |
20140170186 | VIRUS-LIKE PARTICLES AND METHODS OF USE - The invention features modified alphavirus or flavivirus virus-like particles (VLPs). The invention provides methods, compositions, and kits featuring the modified VLPs. The invention also features methods for enhancing production of modified VLPs for use in the prevention or treatment of alphavirus and flavivirus-mediated diseases. The invention also provides methods for delivering agents to a cell using the modified VLPs. | 06-19-2014 |
20140363458 | MALARIA VACCINE - The present invention provides a particle comprising a polypeptide and at least one malaria antigen, and a composition or vaccine comprising thereof, its use in medicine, particularly in the prevention or treatment of malaria infections. | 12-11-2014 |
20150017194 | VIRUS LIKE PARTICLE COMPRISING PD-1 ANTIGEN OR PD-1 LIGAND ANTIGEN - The present invention provides a virus like particle comprising a virus structural protein and an antigen derived from PD-1 or a ligand of PD-1, and a composition or kit comprising thereof, its use in immune response etc. | 01-15-2015 |
20160040134 | VIRUS LIKE PARTICLE COMPRISING MODIFIED ENVELOPE PROTEIN E3 - A virus like particle comprising a viral structural protein which comprises modified envelope protein E3. The viral structural protein may be that derived from or alphavirus or flavivirus. Especially, the viral structural protein may be derived from Chikungunya virus or Venezuelan equine encephalitis virus. | 02-11-2016 |
20160074501 | Flavivirus virus like particle - Provided is a virus like particle comprising one or more flavivirus structural proteins, and a composition or vaccine comprising thereof, its use in the prevention or treatment of flavivirus infection. The flavivirus structural protein contains at least one amino acid alteration in the envelope region. Examples of flavivirus contains dengue virus. | 03-17-2016 |
20160090403 | VIRUS LIKE PARTICLE COMPOSITION - The present invention provides a particle comprising a polypeptide and at least one antigen, and a composition comprising thereof. | 03-31-2016 |